Represents the amortization of capitalized fees paid to a related party.

No definition available.

Name:	thrx_AmortizationOfCapitalizedFeesPaidToRelatedParty
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the number of additional preclinical MABA compounds added to the MABA program.

+ References

No definition available.

+ Details

Name:	thrx_CollaborationArrangementObligationToDiscoverPreclinicalCompounds
Namespace Prefix:	thrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the minimum number of structurally different product candidates which the counterparty entity is obligated to use diligent efforts to discover at its own cost after the collaborator licenses a program.

+ References

No definition available.

+ Details

Name:	thrx_CollaborationArrangementObligationToDiscoverStructurallyDifferentProductsAfterLicense
Namespace Prefix:	thrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate for combination products.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix:	thrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the potential future contingent payments that the entity is eligible to receive.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementContingentPaymentThatEntityCouldEarn
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents potential contingent payments under a collaborative arrangement for programs with a single-agent and combination medicine.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementContingentPaymentThatEntityCouldEarnForSingleAgentAndCombinationMedicine
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents potential contingent payments under a collaborative arrangement for programs with single-agent medicines.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementContingentPaymentThatEntityCouldEarnForSingleAgentMedicine
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount of potential milestone payments that could be payable.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementObligationForMilestonePayments
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the royalty rate for combination products as a percentage of the rate applicable for single products under a collaborative arrangement.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementRoyaltyRateCombinationProductsAsPercentageOfSingleProducts
Namespace Prefix:	thrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix:	thrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix:	thrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue earned under collaborative arrangements from upfront payments and contingent payments.

+ References

No definition available.

+ Details

Name:	thrx_CollaborativeArrangementsRevenue
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the percentage of contingent payments and royalties receivable for sales made by the entity.

+ References

No definition available.

+ Details

Name:	thrx_ContingentPaymentsAndRoyaltiesReceivableAsPercent
Namespace Prefix:	thrx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the increase (decrease) in net loss due to revised performance period.

+ References

No definition available.

+ Details

Name:	thrx_IncreaseDecreaseInProfitLossDueToRevisedEstimatedPerformancePeriod
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents revenue net of amortization expense for capitalized fees paid to a related party during the period from the leasing or otherwise lending to a related party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. An example of property from which royalties may be derived includes patents.

+ References

No definition available.

+ Details

Name:	thrx_RoyaltyRevenueFromRelatedPartyNet
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of shares issued during the period as a result of private placement to a related party.

+ References

No definition available.

+ Details

Name:	thrx_StockIssuedDuringPeriodSharesPrivatePlacementToRelatedParty
Namespace Prefix:	thrx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value stock issued during the period as a result of private placement to a related party, net of issuance cost.

+ References

No definition available.

+ Details

Name:	thrx_StockIssuedDuringPeriodValuePrivatePlacementToRelatedParty
Namespace Prefix:	thrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Balance held at close of period in number of shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-12C.Column B)

-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611225-123010

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 6

-Subparagraph (SX 210.12-14.Column B)

-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611322-123010

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 1

-Subparagraph (SX 210.12-12.Column B)

-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611133-123010

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 12C

-Paragraph Column B

-Article 12

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 12

-Paragraph Column B

-Article 12

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 14

-Paragraph Column B

-Article 12

+ Details

Name:	us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=thrx_GSKMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=thrx_CommonStockUnspecifiedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=thrx_GovernanceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=thrx_LABACollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=thrx_StrategicAllianceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements (Details) (USD $)	3 Months Ended								12 Months Ended			1 Months Ended	3 Months Ended
Collaborative Arrangements (Details) (USD $)	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2011 item	Dec. 31, 2012
Information related to collaborative arrangements
Company's stock purchased by related party									$ 38,095,000	$ 126,030,000	$ 229,296,000
Less: amortization of capitalized fees paid to a related party									(11,066,000)	(743,000)	0
Royalty revenue									7,351,000thrx_RoyaltyRevenueFromRelatedPartyNet	1,202,000thrx_RoyaltyRevenueFromRelatedPartyNet	0thrx_RoyaltyRevenueFromRelatedPartyNet
Revenue from Collaborative Arrangements									1,082,000thrx_CollaborativeArrangementsRevenue	3,330,000thrx_CollaborativeArrangementsRevenue	5,613,000thrx_CollaborativeArrangementsRevenue
Total net revenue	7,280,000us-gaap_Revenues	999,000us-gaap_Revenues	934,000us-gaap_Revenues	(780,000)us-gaap_Revenues	1,473,000us-gaap_Revenues	415,000us-gaap_Revenues	1,322,000us-gaap_Revenues	1,322,000us-gaap_Revenues	8,433,000us-gaap_Revenues	4,532,000us-gaap_Revenues	5,613,000us-gaap_Revenues
Common stock \| Theravance Biopharma
Information related to collaborative arrangements
Number of ordinary shares owned as available-for-sale securities	436,802								436,802
GSK
Information related to collaborative arrangements
Contingent payments and royalties receivable (as a percent)									15.00%
Royalty revenue									18,417,000	1,945,000	0
Less: amortization of capitalized fees paid to a related party									(11,066,000)	(743,000)	0
Royalty revenue									7,351,000	1,202,000	0
Total net revenue									8,433,000	4,532,000	5,613,000
GSK \| Theravance Biopharma
Information related to collaborative arrangements
Contingent payments and royalties receivable (as a percent)									85.00%
GSK \| MABA
Information related to collaborative arrangements
Potential future contingent payments receivable	363,000,000								363,000,000
Long-acting beta agonist (LABA) collaboration \| GSK
Information related to collaborative arrangements
Obligation for milestone payments	220,000,000								220,000,000
Royalty rate for first level of annual global net sales (as a percent)									15.00%
Annual global sales level used to determine royalty rate									3,000,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)									5.00%
Revenue from Collaborative Arrangements									0	1,815,000	3,629,000
Long-acting beta agonist (LABA) collaboration \| GSK \| Minimum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)									6.50%
Long-acting beta agonist (LABA) collaboration \| GSK \| Maximum
Information related to collaborative arrangements
Royalty rate for combination products (as a percent)									10.00%
2004 Strategic alliance \| GSK \| MABA
Information related to collaborative arrangements
Number of products which the Counterparty is obligated to use diligent efforts to discover after license of a program									1
Number of preclinical MABA compounds discovered												6
Revenue from Collaborative Arrangements									1,082,000	1,515,000	1,984,000
Increase in net loss due to revised estimated performance period					100,000								100,000
2004 Strategic alliance \| GSK \| MABA containing '081 \| Maximum
Information related to collaborative arrangements
Potential contingent payments that the Company could receive in respect to single-agent and combination medicines	250,000,000								250,000,000
2004 Strategic alliance \| GSK \| MABA containing '081 - single-agent
Information related to collaborative arrangements
Annual global sales level used to determine royalty rate									3,500,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)									7.50%
2004 Strategic alliance \| GSK \| MABA containing '081 - single-agent \| Minimum
Information related to collaborative arrangements
Royalty rate for first level of annual global net sales (as a percent)									10.00%
2004 Strategic alliance \| GSK \| MABA containing '081 - single-agent \| Maximum
Information related to collaborative arrangements
Royalty rate for first level of annual global net sales (as a percent)									20.00%
Potential contingent payments that the Company could receive	125,000,000								125,000,000
2004 Strategic alliance \| GSK \| MABA containing '081 - combination product
Information related to collaborative arrangements
Royalty rate for combination products as a percentage of the rate applied to single products									70.00%
2004 Strategic alliance \| GSK \| MABA containing additional MABA \| Maximum
Information related to collaborative arrangements
Potential future contingent payments receivable	129,000,000								129,000,000
2004 Strategic alliance \| GSK \| MABA containing additional MABA - single-agent
Information related to collaborative arrangements
Annual global sales level used to determine royalty rate									3,500,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)									10.00%
Royalty rate for combination products as a percentage of the rate applied to single products									50.00%
2004 Strategic alliance \| GSK \| MABA containing additional MABA - single-agent \| Minimum
Information related to collaborative arrangements
Royalty rate for first level of annual global net sales (as a percent)									10.00%
2004 Strategic alliance \| GSK \| MABA containing additional MABA - single-agent \| Maximum
Information related to collaborative arrangements
Royalty rate for first level of annual global net sales (as a percent)									15.00%
Governance agreement \| GSK \| Common stock
Information related to collaborative arrangements
Company's stock purchased by related party (in shares)									1.7
Company's stock purchased by related party									$ 38,100,000